LENZ Therapeutics, Inc. (LENZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	21.5M	19.1M	—	—	15.0M
Cost of Revenue	2.1M	705.0K	58.0K	—	—
Gross Profit	19.4M	18.4M	(58.0K)	—	15.0M
Operating Expenses
R&D Expense	3.8M	18.7M	29.8M	59.5M	21.1M
SG&A Expense	151.2M	90.9M	28.8M	12.9M	4.4M
General & Admin Expense	39.4M	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	155.0M	109.5M	58.6M	72.4M	25.5M
Cost and Expenses	157.1M	110.2M	58.6M	72.4M	25.5M
Operating Income (EBIT)	(135.7M)	(91.1M)	(58.6M)	(72.4M)	(10.5M)
Non-Operating
Interest Income	10.1M	9.8M	8.6M	2.2M	—
Interest Expense	—	—	—	—	—
Net Interest Income	10.1M	9.8M	8.6M	2.2M	—
Other Non-Op Income/Expense	9.7M	9.5M	8.8M	2.3M	19.0K
Non-Operating Income (excl Interest)	(9.7M)	(9.5M)	(8.8M)	(2.3M)	(19.0K)
EBT (Pre-Tax Income)	(126.0M)	(81.6M)	(49.8M)	(70.1M)	(10.5M)
Income Tax Expense	5.0K	502.0K	1.0K	(179.0K)	347.0K
Bottom Line
Net Income	(126.0M)	(82.1M)	(49.8M)	(70.0M)	(10.8M)
Earnings from Cont. Ops	(126.0M)	(82.1M)	(49.8M)	(70.0M)	(10.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(126.0M)	(82.1M)	(49.8M)	(70.0M)	(10.8M)
Per Share
Basic EPS	($4.09)	($2.85)	($2.34)	($15.30)	($12.89)
Diluted EPS	($4.09)	($2.85)	($2.34)	($15.30)	($12.89)
Revenue Per Share	$0.68	$0.66	$0.00	$0.00	$1.91
Shares
Basic Shares Outstanding	31.4M	28.8M	21.3M	8.1M	7.8M
Diluted Shares Outstanding	31.4M	28.8M	21.3M	8.1M	7.8M
Profitability Metrics
EBITDA	(125.5M)	(81.3M)	(49.7M)	(70.1M)	(10.5M)
D&A	453.0K	287.0K	58.0K	15.0K	8.0K
EBIT	(126.0M)	(81.6M)	(49.8M)	(70.1M)	(10.5M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026